Home›Clinical trials›New Jersey

GLP-1 clinical trials in New Jersey: 12 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

12 GLP-1 clinical trials are recruiting at 26 sites in 22 cities across New Jersey. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in New Jersey

  1. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    2 sites in New Jersey

    • Psoriasis Treatment Center of Central New Jersey, East Windsor
    • Care Access - Hoboken, Hoboken. 551-278-8680

  2. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    5 sites in New Jersey
    • Tandem Clinical Research - Freehold, Freehold
    • Atlantic Health System Morristown Medical Center, Morristown. 973-971-7507
    • Clinical Research of Philadelphia, Pennington. 215-676-6696
    • The Cognitive and Research Center of New Jersey - Ridgewood, Ridgewood. 201-850-4622
    • IMA Clinical Research Warren, Warren Township

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    1 site in New Jersey

    • IMA Clinical Research-Warren-69742, Warren Township. 833-602-2368

  4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in New Jersey

    • IMA Clinical Research-Warren-69742, Warren Township. 833-602-2368

  5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    1 site in New Jersey

    • Hackensack University Medical Center, Hackensack

  6. A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07153471.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people ease joint pain.

    Who can join. Adults 18+, have osteoarthritis (joint pain), BMI 27+.

    1 site in New Jersey

  7. A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

    Phase 3. Run by Vanda Pharmaceuticals. Registry number NCT07446439.

    A study testing whether an investigational medicine from Vanda Pharmaceuticals, tradipitant, can help people reduce nausea and vomiting.

    Who can join. Adults 18 to 65, have nausea and vomiting, BMI 25+.

    1 site in New Jersey

  8. Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

    Phase 2. Run by Rutgers, The State University of New Jersey. Registry number NCT06518837.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, may help during breast cancer treatment.

    Who can join. Adults 18+, have hormone-receptor-positive breast cancer, BMI 27+.

    7 sites in New Jersey
    • Trinitas Comprehensive Cancer Center, Elizabeth. 732-235-3374
    • RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton. 732-235-3374
    • RWJBarnabas Health - Cooperman Barnabas, Livingston, Livingston. 732-235-3374
    • RWJBarnabas Health - Monmouth Medical Center, Long Branch. 732-235-3374
    • Rutgers Cancer Institute, New Brunswick. 732-235-3374
    • RWJBarnabas Health - Newark Beth Israel Medical Center, Newark. 732-235-3374
    • RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerville. 732-235-3374

  9. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in New Jersey

  10. A Study of a Weight Loss Intervention in People With Endometrial Cancer

    Phase 1. Run by Memorial Sloan Kettering Cancer Center. Registry number NCT06751589.

    A study of a GLP-1 and GIP medicine, tirzepatide, in people with endometrial cancer.

    Who can join. Adults 18+, women only, have endometrial cancer, BMI 25+.

    3 sites in New Jersey

    • Memorial Sloan Kettering Basking Ridge, Basking Ridge. 646-888-5427
    • Memorial Sloan Kettering Monmouth, Middletown. 646-888-5427
    • Memorial Sloan Kettering Bergen, Montvale. 646-888-5427

  11. Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

    Phase 1. Run by Advanced Reconstructive Surgery Alliance. Registry number NCT07012642.

    A study of a GLP-1 medicine in people with lymphedema.

    Who can join. Adults 18+, have lymphedema, BMI 23+.

    2 sites in New Jersey

  12. A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults

    Phase 1. Run by Shanghai World Leader Pharmaceutical Co., Ltd. Registry number NCT07465965.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

    Who can join. Adults 18 to 65, are overweight, BMI 27+.

    1 site in New Jersey

    • Frontage Clinical Services, Inc., Secaucus. 12014167766

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.